Systematic treatment and prevention of cardiac digoxin toxicity
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20212830Keywords:
Digoxin, Cardiology, Toxicity, ManagementAbstract
Digoxin has a narrow therapeutic index, such as complicated pharmacokinetics and dynamics. Many drug interactions may occur when the administration of one drug alters the clinical effects of another. As a result, digoxin toxicity can be a common condition within clinical settings that might lead to the development of many morbidities and even mortality. Many studies were published to investigate the efficacy and safety of different management modalities to enhance the outcomes that follow digoxin administration. The aim of the study was to discuss the approaches to systematically treat and prevent the development of cardiac digoxin toxicity. The findings are based on evidence from previous studies in the literature. To be specific, Fab fragments are the most effective modalities that can be used to treat severe cases within ideal periods. However, evidence regarding their administration for asymptomatic or mild cases is still poor regarding the cost-efficacy and the development of serious adverse events. Physicians should primarily care for a better intervention as it is usually associated with a significantly more enhanced prognosis and clinical outcomes. Nevertheless, adequate monitoring of the patients and evaluation of their personal and medical history are important steps in the process, and further approaches are still needed. Also, detailed information about our intended outcomes is furtherly discussed within the manuscript.
References
Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28(2):125-36.
Malcom J, Arnold O, Howlett JG, Ducharme A, Ezekowitz JA, Gardner M, et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Can J Cardiol. 2008;24(1):21-40.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):147-239.
Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525-33.
Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64(7):660-8.
Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002-12.
Hashan MR, Ghozy S, Qushayri AE, Pial RH, Hossain MA, Kibria GM. Association of dengue disease severity and blood group: A systematic review and meta-analysis. Rev Med Virol. 2021;31(1):1-9.
Qushayri AE, Ghozy S, Abbas AS, Dibas M, Dahy A, Mahmoud AR, Afifi AM, et al. Hyperimmunoglobulin therapy for the prevention and treatment of congenital cytomegalovirus: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2021;19(5):661-9.
Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD. Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis. 1984;26(5):413-58.
Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD. Digitalis glycosides: mechanisms and manifestations of toxicity. Part II. Prog Cardiovasc Dis. 1984;26(6):495-540.
Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD. Digitalis glycosides: mechanisms and manifestations of toxicity. Part III. Prog Cardiovasc Dis. 1984;27(1):21-56.
Doshchitsin VL. "Digitalis" arrhythmias and their treatment. Kardiologiia. 1976;16(8):26-31.
Park GD, Goldberg MJ, Spector R, Johnson GF, Feldman RD, Quee CK, et al. The effects of activated charcoal on digoxin and digitoxin clearance. Drug Intell Clin Pharm. 1985;19(12):937-41.
Lalonde RL, Deshpande R, Hamilton PP, McLean WM, Greenway DC. Acceleration of digoxin clearance by activated charcoal. Clin Pharmacol Ther. 1985;37(4):367-71.
Rawashdeh NM, Hadidi HF, Irshaid YM, Battah AK. Gastrointestinal dialysis of digoxin using cholestyramine. Pharmacol Toxicol. 1993;72(4):245-8.
Abdelaziz NA, Ghozy S, Salah A, Abbas AR, Qushayri AE, Islam SMS. Full recovery of a patient with COVID-19-induced acute kidney injury. European J Med Case Report. 2021;5(1):26-30.
Smith TW, Haber E, Yeatman L, Butler VP. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med. 1976;294(15):797-800.
Flanagan RJ, Jones AL. Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33.
Antman EM, Wenger TL, Butler VP, Haber E, Smith TW. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81(6):1744-52.
Hickey AR, Wenger TL, Carpenter VP, Tilson HH, Hlatky MA, Furberg CD, et al. Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol. 1991;17(3):590-8.
Amer N, Priel E, Karlish SJD, Farfel Z, Mayan H. Hypermagnesuria in Humans Following Acute Intravenous Administration of Digoxin. Nephron. 2018;138(2):113-8.
Rahim AH, MacIsaac RL, Jhund PS, Petrie MC, Lees KR, Murray JJ, et al. Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. Int J Cardiol. 2016;209:310-6.
Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol. 1992;69(18):108-18.
Thieu H, Bach Dat B, Nam NH, Reda A, Duc NT, Alshareef A, et al. Antibiotic resistance of Helicobacter pylori infection in a children's hospital in Vietnam: prevalence and associated factors. Minerva Med. 2020;111(5):498-501.
Cummings ED, Swoboda HD. Digoxin Toxicity. USA: StatPearls; 2021.
Rehman R, Hai O. Digitalis Toxicity. USA: StatPearls; 2021.
Kaushal R, Bates DW, Landrigan C, McKenna KJ, Clapp MD, Federico F, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285(16):2114-20.
Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29-34.
Leape LL, Lawthers AG, Brennan TA, Johnson WG. Preventing medical injury. QRB Quality review bulletin. 1993;19(5):144-9.
Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Int Med. 1993;8(6):289-94.
Bates DW, Boyle DL, Vander VMB, Schneider J, Leape L. Relationship between medication errors and adverse drug events. J Gen Intern Med. 1995;10(4):199-205.
Gandhi AJ, Vlasses PH, Morton DJ, Bauman JL. Economic impact of digoxin toxicity. Pharmacoeconomics. 1997;12(2):175-81.
Jelliffe RW. An improved method of digoxin therapy. Ann Intern Med. 1968;69(4):703-17.
Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA. 1998;280(15):1311-6.
Potts AL, Barr FE, Gregory DF, Wright L, Patel NR. Computerized physician order entry and medication errors in a pediatric critical care unit. Pediatrics. 2004;113(1):59-63.
Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010;21(9):1550-9.
Ehle M, Patel C, Giugliano RP. Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine. Critical Path Cardiol. 2011;10(2):93-8.
Wofford JL, Ettinger WH. Risk factors and manifestations of digoxin toxicity in the elderly. Am J Emerg Med. 1991;9(2):11-5; discussion 33-4.
Winter ME, Katcher BS, Kimble MA. Basic clinical pharmacokinetics. 5th ed. India: Lippincott Williams & Wilkins; 2004.
Nelson LS, Howland MA, Lewin NA. Goldfrank's toxicologic emergencies. 11th ed. New York, NY: McGraw-Hill; 2019.
Ritschel WA. Handbook of basic pharmacokinetics-including clinical applications. USA: American Pharmacist Association; 1992.
Piro JT. Concepts in clinical pharmacokinetics. 6th ed. Maryland: American Society of Health-System Pharmacists; 2010.
Young IS, Goh EM, McKillop UH, Stanford CF, Nicholls DP, Trimble ER. Magnesium status and digoxin toxicity. Br J Clin Pharmacol. 1991;32(6):717-21.
Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289(13):1652-8.
Glover N, Mink M, Yarema M, Chuang R. Digoxin toxicity: Case for retiring its use in elderly patients?. Can Fam Physician. 2016;62(3):223-8.
Gomes T, Mamdani MM, Juurlink DN. Macrolide-induced digoxin toxicity: a population-based study. Clin Pharmacol Ther. 2009;86(4):383-6.
Palatnick W, Jelic T. Emergency department management of calcium-channel blocker, beta blocker, and digoxin toxicity. Emerg Med Pract. 2014;16(2):1-19
